Arcadia Biosciences (RKDA) Equity Average (2015 - 2025)

Arcadia Biosciences has reported Equity Average for 11 years, with the latest figure at $4.8 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 41.47% year-over-year to $4.8 million; the trailing twelve-month figure through Dec 2025 stood at $4.8 million (down 41.47% YoY), and the FY2025 full-year result was $5.2 million, down 45.24% from the prior year.
• Equity Average for Q4 2025 stood at $4.8 million, down from $5.0 million in the prior quarter.
• The five-year high for Equity Average was $44.2 million in Q2 2021, with the low at $4.8 million in Q4 2025.
• Historically, Equity Average has averaged $19.9 million across 5 years, with a median of $16.9 million in 2023.
• Annual changes were most pronounced in 2021 — Equity Average surged 261.37% — and 2025, when it tumbled 54.06%.
• Arcadia Biosciences' Equity Average stood at $35.7 million in 2021, then slumped by 35.7% to $23.0 million in 2022, then slumped by 38.8% to $14.1 million in 2023, then tumbled by 41.74% to $8.2 million in 2024, then sank by 41.47% to $4.8 million in 2025.
• The last three Equity Average figures came in at $4.8 million (Q4 2025), $5.0 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.